Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Charles H. Chesnut(University of Washington), Arne Høiseth, Arne Skag(University of Bergen), J. A. Stakkestad, Jennifer Gilbride(Roche (United Kingdom)), Claus Christiansen(Université Claude Bernard Lyon 1), Dieter Felsenberg(Freie Universität Berlin), Ralph C. Schimmer(Roche (Switzerland)), Pierre D. Delmas(Inserm), Hermann Huss, Robert R. Recker(Creighton University)
Cited by 1,225
Related Papers
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.4k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
|Osteoporosis International|2007|1.2k